JANX vs NBIX · rev $10.3M vs P/E 45, rev $1.77B
Janux Therapeutics Inc (JANX) versus Neurocrine Biosciences Inc (NBIX) — a side-by-side from cached financials, not a winner call.
Janux Therapeutics Inc (JANX) is a biotechnology company listed on US.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Latest reported JANX revenue for 2026-06-30 was $10.3M. Net income was -$22.0M. JANX currently screens at market cap $1.49B.
Latest reported NBIX revenue for 2026-06-30 was $1.77B. Net income was $342.3M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
JANX currently screens at market cap $1.49B. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Not investment advice. Open the JANX and NBIX stock pages for the full models.
Not investment advice.